Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006324 · ClinicalTrials.gov registry record · NA

Hormonal Birth Control and the Risk of Acquiring HIV

A NA study, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Completed
Registry status
NA
Development phase
6,360
Enrollment target

NCT00006324 is a NA study that has completed, run by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The registered enrollment target is 6,360 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006324, a NA study, has completed, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

COMPLETED
Registry status
NA
Development phase
6,360 participants
Enrollment target

Study Summary

The purpose of this study is to find out whether hormonal birth control increases, decreases, or does not change the risk of women becoming infected with HIV. Sexual intercourse between men and women is the main way HIV is transmitted. About 90 percent of HIV infections in women are caused by sexual intercourse. Also, hormonal birth controls are widely used. This study hopes to find out whether hormonal birth control changes the risk of women becoming infected with HIV.

Interventions

  • DRUG Medroxyprogesterone acetate
  • DRUG Ethinyl estradiol/levonorgestrel

Trial Details

FieldValue
Enrollment Target 6,360 participants
Start Date 1999-12
Est. Completion 2002-12
Phase NA

What the Registry Record Tells You About NCT00006324

The ClinicalTrials.gov registry entry for NCT00006324 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6,360 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Medroxyprogesterone acetate is the first listed.

NCT00006324 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00006324 about?

NCT00006324 is a clinical study titled "Hormonal Birth Control and the Risk of Acquiring HIV". The purpose of this study is to find out whether hormonal birth control increases, decreases, or does not change the risk of women becoming infected with HIV. Sexual intercourse between men and women is the main way HIV is transmitted. About 90 percent of HIV infections in women are caused by sexua...

What is the current status of trial NCT00006324?

This trial is currently completed. It is a NA study. The enrollment target is 6,360 participants. The study started on 1999-12. Estimated completion is 2002-12.

What interventions are being tested in trial NCT00006324?

The interventions under investigation include: Medroxyprogesterone acetate (DRUG), Ethinyl estradiol/levonorgestrel (DRUG).

Who is sponsoring clinical trial NCT00006324?

This trial is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), which has 305 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.